Principal Financial Group Inc Athenex, Inc. Transaction History

Principal Financial Group Inc

  • $172 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022
SELL
$0.41 - $0.91 $9,592 - $21,291
-23,397 Closed
0 $0
Q1 2022

May 09, 2022
SELL
$0.79 - $1.59 $551 - $1,109
-698 Reduced 2.9%
23,397 $19,000
Q4 2021

Feb 09, 2022
SELL
$1.36 - $2.94 $10,715 - $23,164
-7,879 Reduced 24.64%
24,095 $33,000
Q3 2021

Nov 09, 2021
SELL
$2.97 - $4.84 $5,381 - $8,770
-1,812 Reduced 5.36%
31,974 $96,000
Q2 2021

Aug 10, 2021
BUY
$3.71 - $5.13 $493 - $682
133 Added 0.4%
33,786 $156,000
Q1 2021

May 10, 2021
SELL
$4.08 - $14.75 $4,785 - $17,301
-1,173 Reduced 3.37%
33,653 $145,000
Q4 2020

Feb 08, 2021
BUY
$11.06 - $14.01 $210,704 - $266,904
19,051 Added 120.77%
34,826 $385,000
Q3 2020

Nov 06, 2020
SELL
$10.26 - $14.55 $132,754 - $188,262
-12,939 Reduced 45.06%
15,775 $190,000
Q2 2020

Aug 05, 2020
BUY
$7.11 - $13.76 $120,080 - $232,392
16,889 Added 142.82%
28,714 $395,000
Q1 2020

May 12, 2020
BUY
$5.71 - $15.85 $3,094 - $8,590
542 Added 4.8%
11,825 $92,000
Q4 2019

Feb 05, 2020
BUY
$9.6 - $17.75 $7,948 - $14,697
828 Added 7.92%
11,283 $172,000
Q3 2019

Nov 13, 2019
BUY
$12.16 - $21.0 $2,152 - $3,717
177 Added 1.72%
10,455 $127,000
Q2 2019

Aug 12, 2019
BUY
$9.44 - $19.8 $97,024 - $203,504
10,278 New
10,278 $204,000

Others Institutions Holding ATNX

# of Institutions
3
Shares Held
1.46M
Call Options Held
0
Put Options Held
0
View Full List

About Athenex, Inc.

ATNX Quotes by TradingView
  • Ticker ATNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 156,790,000
  • Market Cap $1.57M
  • Description
  • Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...
More about ATNX
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email